Q-omics provides the consensus-scored IQCF3 profile across patient tissues and cancer cell-line models. IQCF3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IQCF3 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, IQCF3 RNA expression shows 6,768 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where IQCF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IQCF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IQCF3 survival associations across molecular data types. IQCF3 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IQCF3 RNA expression–survival associations across cancer types. High IQCF3 expression shows unfavorable associations in THCA, BLCA, READ and COAD, but favorable associations in KIRP and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for IQCF3 RNA expression.
This table summarizes IQCF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IQCF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IQCF3 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in BLCA, LUAD and THCA. The KIRC box plot shows higher IQCF3 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .002).
This table shows molecular features associated with IQCF3 in patient tissues and cancer cell lines. In patient samples, IQCF3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IQCF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
